Perrigo (PRGO +0.5%) announces final FDA approval for its Ketoconazole Foam 2% treatment for dermatitis in younger patients. The company has commenced shipping of the product and has 180 days of marketing exclusivity.
Sent to 1,854 people who get email alerts on PRGO.
Get email alerts on PRGO »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $20.